Comparison of Nikkomycin Z Bioavailability Under Fed and Fasting Conditions

Healthy Clinical Trial

Official title:

Comparison of Nikkomycin Z Bioavailability After Single Dose Administration Under Fed (High Fat Meal) Compared to Fasting Conditions

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01647256
• Other study ID #: VFCE-2011-004
• Status: Terminated
• Phase: Phase 1
• First received: July 16, 2012
• Last updated: September 16, 2013
• Start date: July 2012
• Est. completion date: June 2013

Study information

• Verified date: September 2013
• Source: University of Arizona
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to evaluate if eating a high fat meal versus not eating any food affects how the study drug (Nikkomycin Z) is absorbed into the body. The second purpose is to gain further information about the safety of Nikkomycin Z in healthy adults.

Description:

To compare the single-dose bioavailability of Nikkomycin Z 500 mg (two 250 mg capsules) under fed and fasting conditions.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: June 2013
• Est. primary completion date: August 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Be at least 18 years of age and not over 40 years of age

• Be male, or female (non childbearing potential or using adequate contraception)

• Have a body mass index between 18 and 29 kg/m2

• Able to understand the study and give written informed consent

• Be determined healthy based on a medical and laboratory evaluation

Exclusion Criteria:

• Patients under the age of 18 years or over 40 years of age

• Current smoker or history of smoking within 3 months of participation

• Inability to comprehend study and provide written informed consent

• Inability to comply with the study requirements

• History of or current evidence of major organ disease

• Renal disease - serum creatinine > 1.5 mg/dL, significant hematuria or proteinuria, known structural abnormality or chronic kidney disease

• Hepatic disease - active viral hepatitis, history of hepatitis B or hepatitis C, bilirubin > 2.0, ALT or AST above normal upper limit for laboratory, alcoholic liver disease, other chronic liver disease

• CNS disease or cognitive dysfunction - any past history of epilepsy, CNS infections, stroke, CNS bleed, severe headaches, major psychiatric illness, or current mental status changes

• Lung disease - history of severe asthma, COPD, pulmonary tuberculosis, or other major lung disease

• Cardiac disease - history or current evidence of ischemic coronary artery disease, myocardial infarction, heart failure, or significant arrhythmia

• Gastrointestinal disease - presence of inflammatory bowel disease, difficulty swallowing, or any gastrointestinal probably that would limit taking oral medications or that may compromise absorption of oral medications

• Cancer - History of hematologic malignancy or solid tumor excluding basal cell carcinoma limited to the skin within the past 5 years

• History of autoimmune or inflammatory disease such as rheumatoid arthritis and lupus

• Immunocompromised state - solid organ transplant, cancer chemotherapy, stem cell transplant with graft versus host disease, immunosuppressive therapy, or HIV infection

• Recent weight loss of greater than 10%

• Any other history or evidence of disease that in the opinion of the physician would increase the risk for the subject for clinical trial participation

• Regular use of prescription medications, over-the-counter medications, or dietary/herbal supplements within 14 days of day 1. Occasional use of acetaminophen or over-the-counter NSAID within the 14 day window may be allowed at the P.I. discretion

• Subjects who received another investigational drug within 30 days of enrollment

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Nikkomycin Z
Capsule, 500 mg, single-dose

Locations

Country	Name	City	State
United States	University of Arizona - Clinical and Translational Science Research Center	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate and extent of Nikkomycin Z absorption under fed and fasting conditions		24 hours	No
Secondary	Extent of Nikkomycin Z urinary excretion		24 hours	Yes